BioLineRx (BLRX) Competitors

BioLineRx logo
$0.96 -0.10 (-9.07%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$0.98 +0.01 (+1.15%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BLRX vs. ACET, IZTC, MGX, GNTA, and EVAX

Should you buy BioLineRx stock or one of its competitors? BioLineRx's main competitors and comparable companies include Adicet Bio (ACET), Invizyne Technologies (IZTC), Metagenomi (MGX), Genenta Science (GNTA), and Evaxion A/S (EVAX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does BioLineRx compare to Adicet Bio?

Adicet Bio (NASDAQ:ACET) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

BioLineRx has higher revenue and earnings than Adicet Bio. BioLineRx is trading at a lower price-to-earnings ratio than Adicet Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Adicet BioN/AN/A-$116.80M-$8.57N/A
BioLineRx$1.18M4.07-$1.17M-$1.69N/A

Adicet Bio has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Adicet Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Adicet BioN/A -69.71% -56.97%
BioLineRx -502.08%-34.80%-18.27%

83.9% of Adicet Bio shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 3.4% of Adicet Bio shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Adicet Bio presently has a consensus price target of $37.80, suggesting a potential upside of 1,666.36%. Given Adicet Bio's stronger consensus rating and higher possible upside, analysts plainly believe Adicet Bio is more favorable than BioLineRx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adicet Bio
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00
BioLineRx
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, BioLineRx had 4 more articles in the media than Adicet Bio. MarketBeat recorded 4 mentions for BioLineRx and 0 mentions for Adicet Bio. Adicet Bio's average media sentiment score of 0.00 equaled BioLineRx'saverage media sentiment score.

Company Overall Sentiment
Adicet Bio Neutral
BioLineRx Neutral

Adicet Bio has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market. Comparatively, BioLineRx has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

Summary

Adicet Bio beats BioLineRx on 9 of the 15 factors compared between the two stocks.

How does BioLineRx compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

1.6% of BioLineRx shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invizyne Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
BioLineRx
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Invizyne Technologies has higher earnings, but lower revenue than BioLineRx.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invizyne TechnologiesN/AN/AN/AN/AN/A
BioLineRx$1.18M4.07-$1.17M-$1.69N/A

Invizyne Technologies has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. Invizyne Technologies' return on equity of 0.00% beat BioLineRx's return on equity.

Company Net Margins Return on Equity Return on Assets
Invizyne TechnologiesN/A N/A N/A
BioLineRx -502.08%-34.80%-18.27%

In the previous week, BioLineRx had 3 more articles in the media than Invizyne Technologies. MarketBeat recorded 4 mentions for BioLineRx and 1 mentions for Invizyne Technologies. Invizyne Technologies' average media sentiment score of 0.00 equaled BioLineRx'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Invizyne Technologies
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioLineRx
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

BioLineRx beats Invizyne Technologies on 5 of the 8 factors compared between the two stocks.

How does BioLineRx compare to Metagenomi?

BioLineRx (NASDAQ:BLRX) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Metagenomi has a consensus target price of $6.00, indicating a potential upside of 950.79%. Given Metagenomi's stronger consensus rating and higher possible upside, analysts clearly believe Metagenomi is more favorable than BioLineRx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLineRx
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Metagenomi
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

In the previous week, BioLineRx had 4 more articles in the media than Metagenomi. MarketBeat recorded 4 mentions for BioLineRx and 0 mentions for Metagenomi. BioLineRx's average media sentiment score of 0.00 equaled Metagenomi'saverage media sentiment score.

Company Overall Sentiment
BioLineRx Neutral
Metagenomi Neutral

1.6% of BioLineRx shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 12.5% of Metagenomi shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

BioLineRx has higher earnings, but lower revenue than Metagenomi. BioLineRx is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLineRx$1.18M4.07-$1.17M-$1.69N/A
Metagenomi$7.09M3.05-$87.87M-$2.50N/A

BioLineRx has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market. Comparatively, Metagenomi has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

Metagenomi has a net margin of -384.61% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Metagenomi's return on equity.

Company Net Margins Return on Equity Return on Assets
BioLineRx-502.08% -34.80% -18.27%
Metagenomi -384.61%-75.04%-50.29%

Summary

BioLineRx beats Metagenomi on 8 of the 15 factors compared between the two stocks.

How does BioLineRx compare to Genenta Science?

BioLineRx (NASDAQ:BLRX) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioLineRx
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

BioLineRx has a beta of 1.64, indicating that its share price is 64% more volatile than the broader market. Comparatively, Genenta Science has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market.

In the previous week, BioLineRx had 4 more articles in the media than Genenta Science. MarketBeat recorded 4 mentions for BioLineRx and 0 mentions for Genenta Science. BioLineRx's average media sentiment score of 0.00 equaled Genenta Science'saverage media sentiment score.

Company Overall Sentiment
BioLineRx Neutral
Genenta Science Neutral

BioLineRx has higher revenue and earnings than Genenta Science.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioLineRx$1.18M4.07-$1.17M-$1.69N/A
Genenta ScienceN/AN/A-$7.39MN/AN/A

1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Genenta Science has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. Genenta Science's return on equity of 0.00% beat BioLineRx's return on equity.

Company Net Margins Return on Equity Return on Assets
BioLineRx-502.08% -34.80% -18.27%
Genenta Science N/A N/A N/A

Summary

Genenta Science beats BioLineRx on 5 of the 9 factors compared between the two stocks.

How does BioLineRx compare to Evaxion A/S?

Evaxion A/S (NASDAQ:EVAX) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

BioLineRx has lower revenue, but higher earnings than Evaxion A/S. Evaxion A/S is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evaxion A/S$7.49M2.71-$7.71M-$2.44N/A
BioLineRx$1.18M4.07-$1.17M-$1.69N/A

Evaxion A/S has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.64, indicating that its stock price is 64% more volatile than the broader market.

Evaxion A/S has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Evaxion A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Evaxion A/SN/A -126.83% -70.63%
BioLineRx -502.08%-34.80%-18.27%

Evaxion A/S presently has a consensus target price of $11.25, indicating a potential upside of 400.00%. Given Evaxion A/S's stronger consensus rating and higher possible upside, research analysts clearly believe Evaxion A/S is more favorable than BioLineRx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evaxion A/S
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
BioLineRx
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Evaxion A/S had 4 more articles in the media than BioLineRx. MarketBeat recorded 8 mentions for Evaxion A/S and 4 mentions for BioLineRx. BioLineRx's average media sentiment score of 0.00 beat Evaxion A/S's score of -0.36 indicating that BioLineRx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Evaxion A/S
0 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioLineRx
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Evaxion A/S and BioLineRx tied by winning 8 of the 16 factors compared between the two stocks.

Get BioLineRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLRX vs. The Competition

MetricBioLineRxBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$4.80M$3.92B$7.44B$10.86B
Dividend YieldN/A3.79%2.51%4.60%
P/E Ratio-0.5723.0732.5628.68
Price / Sales3.4514.847.815.19
Price / CashN/A21.9220.2520.77
Price / Book0.184.124.343.51
Net Income-$1.17M-$24.08M$3.51B$394.12M
7 Day Performance-23.56%-9.85%-8.07%-8.97%
1 Month Performance-52.75%-12.77%-10.29%-11.61%
1 Year Performance-70.34%-7.99%-4.70%-11.21%

BioLineRx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BLRX
BioLineRx
0.2741 of 5 stars
$0.96
-9.1%
N/A-70.3%$4.80M$1.39MN/A22
ACET
Adicet Bio
3.4438 of 5 stars
$3.00
+0.3%
$37.80
+1,160.0%
-77.8%$28.08MN/AN/A102
IZTC
Invizyne Technologies
N/A$4.28
-2.8%
N/A-82.0%$26.73MN/AN/A29
MGX
Metagenomi
2.2648 of 5 stars
$0.70
-3.0%
$6.00
+757.1%
-62.2%$26.45M$25.21MN/A113
GNTA
Genenta Science
N/A$1.10
+11.0%
N/A-34.6%$25.93MN/AN/A9

Related Companies and Tools


This page (NASDAQ:BLRX) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners